Bengt Rasmussen
Oerebro, T, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.
Journal: Genes, chromosomes & cancer
Published: September 05, 2024
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes.
Journal: Journal of internal medicine
Published: April 24, 2024
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 17, 2024
MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients.
Journal: Leukemia research
Published: May 15, 2023
Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.
Journal: Leukemia
Published: October 19, 2022
Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes.
Journal: European journal of haematology
Published: February 25, 2021
Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
Journal: British journal of haematology
Published: March 06, 2020
Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Journal: British journal of haematology
Published: November 23, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026